SOCS1 (Suppressor of Cytokine Signaling 1) is a critical negative regulator of cytokine signaling that functions primarily through inhibition of the JAK-STAT pathway 1. The protein acts as both a direct kinase inhibitor and an E3 ubiquitin ligase component, binding to JAK proteins to suppress their kinase activity and targeting specific proteins for ubiquitin-mediated degradation 2. SOCS1 regulates multiple inflammatory pathways by controlling the cellular response to interferons, interleukins, and other cytokines, with particular importance in immune cell differentiation and macrophage polarization 3. Disease associations include familial autoinflammatory syndromes, with heterozygous SOCS1 variants causing incomplete penetrance that shows female predominance and manifests as allergic, gastrointestinal, rheumatological, and lymphoproliferative disorders 1. SOCS1 dysfunction is implicated in various malignancies, including diffuse large B-cell lymphoma where mutations correlate with reduced survival 4, and acute lymphoblastic leukemia where polymorphisms affect disease susceptibility 5. Clinically, JAK inhibitors show promising therapeutic efficacy in treating SOCS1 insufficiency, providing targeted therapy for affected patients 1. The protein's dual role as both kinase inhibitor and ubiquitin ligase makes it a central checkpoint molecule in immune homeostasis.